Search
Ropivacaine
go.drugbank.com/drugs/DB00296ApprovedInvestigationalRopivacaine is an aminoamide local anesthetic drug marketed by AstraZeneca under the trade name Naropin. … It exists as a racemate of its S- and R-enantiomers, although the marketed form is supplied only as the purified S-enantiomer.[L42140]
Synonyms: L-N-n-propylpipecolic acid-2,6-xylidideFlorbetaben F-18
go.drugbank.com/drugs/DB09148ApprovedInvestigationalFlorbetaben is a fluorine-18 (18F)-labeled stilbene derivative used for Positron Emission Tomography (PET) imaging of the brain. This radioactive diagnostic drug is used for the non-invasive detection of the density of beta-amyloid plaqu...
Synonyms: 4-((1E)-2-(4-(2-(2-(2-((SUP 18(F))FLUOROETHOXY)ETHOXY)ETHOXY)PHENYL)ETH-1-EN-1-YL)-N-METHYLANILINEPhentermine
go.drugbank.com/drugs/DB00191ApprovedIllicitInvestigationalThis initial product, formed by the combination of phentermine with [fenfluramine] and [dexfenfluramine] was discontinued after finding several reports of abnormal valves in nearly 30% of the consumers
Etofamide
go.drugbank.com/drugs/DB13258ApprovedEtofamide, under the brand name Kitnos, was marketed in Brazil by Pfizer but has been discontinued [L5617].
Xamoterol
go.drugbank.com/drugs/DB13781ApprovedIt modulates the sympathetic control of the heart but has no agonist action on β2-adrenoceptors.
Insulin aspart
go.drugbank.com/drugs/DB01306ApprovedInvestigationalInsulin aspart is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. … Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle.
Denosumab
go.drugbank.com/drugs/DB06643ApprovedInvestigational[A263066] Denosumab was approved by the FDA approved on June 2010 for the treatment of osteoporosis in postmenopausal women. … Two denosumab biosimilars—Wyost® (denosumab-bbdz) [L53063] and Jubbonti® (denosumab-bbdz)[L53058]—were approved by the FDA in March 2024 for all indications of the reference products Xgeva® and Prolia®
Pramlintide
go.drugbank.com/drugs/DB01278ApprovedInvestigationalPramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. … It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes.
Fluoroestradiol F-18
go.drugbank.com/drugs/DB15690ApprovedInvestigational[A203912] Fluoroestradiol F-18 was first granted FDA approval in May 2020, and will be developed by PETNET Solutions, Inc. and Zionexa USA under the brand name Cerianna. … vivo_ is advantageous in that, while helping to visualize tumor progression/regression, it may also be used to assess for heterogeneity in ER expression across metastases (i.e. to identify sites that no
Dacarbazine
go.drugbank.com/drugs/DB00851ApprovedInvestigational(from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.